Plymouth Meeting, PA – February 27 2016: CRF Health, the leading global provider of patient-centered eSource technology and service solutions for the life sciences industry, today announced that its TrialConsent™ electronic informed consent solution has been shortlisted for the ‘Best Patient-Focused Technological Development’ category at this year’s Clinical & Research Excellence (CARE) Awards. The category acknowledges the disruptive role that digital health technology is currently playing in clinical trials.
CRF Health’s TrialConsent is an end-to-end digital platform for the development, collection and management of electronic informed consent. Featuring rich multimedia, tiered-learning and interactive learning assessments, the technology improves recruitment and retention rates through better comprehension of consent materials by trial participants. TrialConsent allows for greater consistency and control in the informed consent process in order to reduce regulatory risk. The ‘Best Patient-Focused Technology Development’ category assesses participants on their ability to gather high-quality patient data via digital tools, and which solutions represent the best advance in improving data collection and/or the patient experience in clinical trials.
The CARE Awards, which take place in Boston on April 5th 2017, aim to celebrate achievements across the clinical research industry. Attended by distinguished leaders in the biopharmaceutical, CRO and diagnostic industries from all corners of the globe, the awards cover activities across the whole industry of clinical research to recognize and reward success.
“With TrialConsent, we’ve worked alongside sponsors, sites and IRBs to understand their needs and to develop an intuitive eConsent platform that is robust and reliable, yet incredibly easy-to-use, and we are delighted that our solution has been shortlisted as a finalist in the 2017 CARE Awards,” commented CRF Health’s CEO, Rachael Wyllie. “TrialConsent allows trial designs to easily integrate electronic informed consent and eCOA solutions on a single platform and even on the same device. By combining eConsent and eCOA, the solution removes the need for a separate consenting technology to be used, significantly reducing complexity for researchers. Importantly, the technology makes the informed consent process more effective and more efficiently streamlined for all stakeholders.”
For further information on CRF Health and the TrialConsent solution, please visit www.crfhealth.com.
About CRF Health
CRF Health is the leading provider of patient-centered eSource and telemedicine technologies and service solutions for the life sciences industry. With experience in more than 800 clinical trials, over 100 languages and across 74 countries, CRF Health’s TrialMax® platform consistently demonstrates the industry’s highest data accuracy, patient and site compliance, and patient retention. Its recent acquisition of mHealth provider Entra Health, has allowed CRF Health to extend the connectivity of its existing technology to now include cloud-based remote patient monitoring, telehealth, data exchange and analytics.
CRF Health’s eSource solutions improve trial engagement by making the patient the center piece of the healthcare and clinical trial process, and seamlessly integrating into sites to maximize protocol compliance. The integrated TrialMax platform includes eCOA solutions for collecting PROs (Patient Reported Outcomes), ObsROs (Observer Reported Outcomes), ClinROs (Clinician or Rater Reported Outcomes), and PerfOs (Performance Outcomes), and features TrialConsent™, an electronic solution for collecting informed consent in clinical trials.
Contact: email@example.com, +1 267.498.2350
About the Author